Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59746-0001-03 59746-0001 Methylprednisolone Methylprednisolone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct. 31, 1997 In Use
59676-0966-02 59676-0966 doxorubicin hydrochloride Doxorubicin Hydrochloride liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous June 26, 2017 Oct. 31, 2020 No Longer Used
59676-0966-01 59676-0966 doxorubicin hydrochloride Doxorubicin Hydrochloride liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous June 26, 2017 Sept. 30, 2020 No Longer Used
59676-0960-02 59676-0960 Doxorubicin Hydrochloride Doxil 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Nov. 17, 1995 June 30, 2020 No Longer Used
59676-0960-01 59676-0960 Doxorubicin Hydrochloride Doxil 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Nov. 17, 1995 Sept. 30, 2020 No Longer Used
59676-0610-01 59676-0610 Trabectedin Yondelis 0.05 mg/mL Chemotherapy Alkylating Agent Natural Product Intravenous Oct. 23, 2015 In Use
59676-0604-30 59676-0604 Apalutamide ERLEADA 240.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 17, 2023 In Use
59676-0604-14 59676-0604 Apalutamide ERLEADA 240.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 17, 2023 In Use
59676-0600-99 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 Nov. 30, 2019 In Use
59676-0600-56 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 1, 2019 In Use
59676-0600-12 59676-0600 Apalutamide ERLEADA 60.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Feb. 14, 2018 In Use
59676-0340-01 59676-0340 Erythropoietin Procrit 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0340-00 59676-0340 Erythropoietin Procrit 40000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0320-04 59676-0320 Erythropoietin Procrit 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0320-01 59676-0320 Erythropoietin Procrit 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Sept. 13, 2012 In Use
59676-0320-00 59676-0320 Erythropoietin Procrit 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0312-04 59676-0312 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0312-01 59676-0312 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Sept. 13, 2012 In Use
59676-0312-00 59676-0312 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0310-02 59676-0310 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0310-01 59676-0310 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0310-00 59676-0310 Erythropoietin Procrit 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0304-02 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0304-01 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0304-00 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0303-02 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0303-01 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0303-00 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0302-02 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0302-01 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0302-00 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59651-0636-03 59651-0636 ISOTRETINOIN ISOTRETINOIN 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0635-03 59651-0635 ISOTRETINOIN ISOTRETINOIN 35.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0634-03 59651-0634 ISOTRETINOIN ISOTRETINOIN 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0633-03 59651-0633 ISOTRETINOIN ISOTRETINOIN 25.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0632-03 59651-0632 ISOTRETINOIN ISOTRETINOIN 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0631-03 59651-0631 ISOTRETINOIN ISOTRETINOIN 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0532-10 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-03 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0523-01 59651-0523 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
59651-0516-30 59651-0516 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 20, 2022 In Use

Found 10,000 results in 14 milliseconds — Export these results